MyDrHank vs Nolu
Two GLP-1 desks, one scoreboard. We put MyDrHank and Nolu head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Nolu takes this head-to-head.
Nolu scores 79 to 74 on our six-factor Brief Score — An all-in, LegitScript-verified GLP-1 line with a simple sticker price — billed every 4 weeks rather than by the calendar month, and with no named prescriber or pharmacy behind it.
That doesn't make MyDrHank a bad call — it's best for readers who already intend to prepay a year up front and want one account covering glp-1 alongside nad+, sermorelin and four other lines — and who will check the term attached to a price before treating it as a monthly bill. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| MyDrHank | Nolu | |
|---|---|---|
| Brief Score | 74/100 (C) | 79/100 (C) |
| Semaglutide | $259/mo (month-to-month; prepay tiers lower) | $249/mo injectable · $279/mo oral (billed per 4 weeks) |
| Tirzepatide | $349/mo (month-to-month; prepay tiers lower) | $339/mo injectable (billed per 4 weeks) |
| Coverage | 44 states (not KS, LA, MS, NM, ND, WV) | All 50 states + DC |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Newnew to the tracker, no prior reading |
MyDrHank: First reading. The funnel advertises "from $240" tirzepatide and "from $171" semaglutide; both are twelve-month prepay rungs, and the month-to-month rates — $349 and $259 — appear on no page of it.
Nolu: First reading — all-in per-order pricing, but billed every 4 weeks rather than by the calendar month.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.